Click in for more news from The Hill {beacon} Health Care Health Care The Big Story Trump officials reject Medicare coverage of anti-obesity drugs The Trump administration says it will not move ...

President Trump’s administration has made the decision not to cover highly-popular obesity treatments under the 2026 Medicare Advantage and Part D policies. One day after the Senate confirmed Dr ...

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million Americans on ...

The obesity drugs cost Medicare and Medicaid hundreds of dollars per patient each month, though the exact prices are secret. Many employers and private health insurance plans do not cover the drugs.

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

Medicare coverage for anti-obesity drugs was not finalized, affecting drugs like Wegovy and Zepbound. Covering weight loss drugs may cost $35 billion from 2026–2034, with estimated savings under ...

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its ...

The Biden administration proposal on obesity drugs. In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in ...